advm-043
Gene therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2017 (NCT02168686)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Alpha-1-antiproteinaseSupplementation
SERPINA1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- advm-043
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02168686 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2017 | Adverum Biotechnologies, Inc., Medical University of South Carolina, Temple University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adverum Biotechnologies, Inc. | For profit | 1 | 1 | 1 | 2017 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1